Effect of diet-ingested pirfenidone on pulmonary function, cardiovasculature and blood gas measurements in rats

Jim K. Mansoor, Andrew T. Chen, Edward S Schelegle, Shri Giri

Research output: Contribution to journalArticle

5 Scopus citations


Pirfenidone is an antifibrotic drug that we have shown attenuates the increase in collagen buildup in hamsters exposed to bleomycin, in turn reducing pulmonary function and blood gas decrements seen in this model of interstitial pulmonary fibrosis. The systemic effects of pirfenidone ingestion, however, are unknown. We examined the effect of diet-ingested pirfenidone on pulmonary function, systemic and pulmonary cardiovasculature and blood gas measurements, breathing pattern and lung hydroxyproline content in rats fed either a control diet or a diet containing 0.5% pirfenidone. Residual volume was higher and expiratory reserve volume lower in the pirfenidone group, with no change in functional residual capacity. Tidal volume was also lower in the pirfenidone group, with no change in the overall level of ventilation. There was a trend toward a reduced hydroxyproline content and an increased lung compliance in the pirfenidone group. There were no differences in systemic or pulmonary pressures, cardiac output, stroke volume, heart rate, pH or blood gases between the two groups. These data indicate that pirfenidone has few systemic side-effects but may have a mild effect on the basal level of lung collagen content with resulting clinical changes in some pulmonary function measurements and changes in breathing pattern.

Original languageEnglish (US)
Pages (from-to)260-268
Number of pages9
JournalResearch Communications in Molecular Pathology and Pharmacology
Issue number3
StatePublished - Mar 1999


ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pathology and Forensic Medicine

Cite this